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Abstract
Background: All sectors of the economy, including the health research sector, must reduce their carbon emissions.
The UK National Institute for Health Research has recently prepared guidelines on how to minimize the carbon
footprint of research. We compare the carbon emissions from two international clinical trials in order to identify
where emissions reductions can be made.
Methods: We conducted a carbon audit of two clinical trials (the CRASH-1 and CRASH-2 trials), quantifying the
carbon dioxide emissions produced over a one-year audit period. Carbon emissions arising from the coordination
centre, freight delivery, trial-related travel and commuting were calculated and compared.
Results: The total emissions in carbon dioxide equivalents during the one-year audit period were 181.3 tonnes for
CRASH-1 and 108.2 tonnes for CRASH-2. In total, CRASH-1 emitted 924.6 tonnes of carbon dioxide equivalents
compared with 508.5 tonnes for CRASH-2. The CRASH-1 trial recruited 10,008 patients over 5.1 years, corresponding
to 92 kg of carbon dioxide per randomized patient. The CRASH-2 trial recruited 20,211 patients over 4.7 years,
corresponding to 25 kg of carbon dioxide per randomized patient. The largest contributor to emissions in CRASH-1
was freight delivery of trial materials (86.0 tonnes, 48% of total emissions), whereas the largest contributor in
CRASH-2 was energy use by the trial coordination centre (54.6 tonnes, 30% of total emissions).
Conclusions: Faster patient recruitment in the CRASH-2 trial largely accounted for its greatly increased carbon
efficiency in terms of emissions per randomized patient. Lighter trial materials and web-based data entry also
contributed to the overall lower carbon emissions in CRASH-2 as compared to CRASH-1.
Trial Registration Numbers: CRASH-1: ISRCTN74459797
CRASH-2: ISRCTN86750102
Background
In November 2008, England became the first country in
the world to establish a legally binding agreement to
reduce carbon emissions by 80% from 1990 levels by
2050 [1]. This requires action to be taken by all sectors
of the economy, including the health and health
research sectors. The National Institute for Health
Research (NIHR) and the Universities that conduct
NIHR funded research are therefore required to reduce
their carbon footprint. The need for caution in relation
to the environmental impacts of medical research is also
stated in the Declaration of Helsinki [2]. The NIHR has
recently drafted guidelines for researchers to improve
the carbon efficiency of their clinical research (http://
www.nihr.ac.uk/publications/Pages/carbon_reduction_-
guidelines.aspx, Table 1).
The CRASH-1 and CRASH-2 trials were international
multi centre randomized controlled trials conducted by
the London School of Hygiene & Tropical Medicine
(LSHTM). The CRASH-1 trial (April 1999- May 2004)
evaluated the effect of corticosteroid administration on
patient outcomes after traumatic brain injury. The
CRASH-2 trial (May 2005- February 2010) examined
the effect of tranexamic acid administration in bleeding
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trauma patients. The two trials were of similar design
but greater effort was made to reduce the carbon foot-
print of the CRASH-2 trial using several of the strategies
outlined in the NIHR carbon reduction guidelines. In
this study we compared the greenhouse gas emissions of
the CRASH-1 and CRASH-2 clinical trials.
Methods
A carbon audit was conducted of the CRASH-1 and
CRASH-2 clinical trials in collaboration with the Edin-
burgh Centre for Carbon Management (ECCM). The
ECCM has completed over 1,100 greenhouse gas quanti-
fications for public and private sector bodies. For each
trial, carbon emissions were calculated for a one-year per-
iod corresponding to steady state patient recruitment for
each trial (CRASH-1: August 2003 to July 2004, CRASH-
2: August 2008 to July 2009). Data were collected on all
trial elements that would generate carbon emissions
according to the greenhouse gas reporting protocol devel-
oped by the World Business Council for Sustainable
Development (WBCSD) [3] (Table 2). Greenhouse gas
emissions were estimated using conversion factors from
the Department for Environment, Food and Rural Affairs,
Intergovernmental Panel on Climate Change (IPCC), the
Swiss Centre for Lifecycle Inventories (SCLCI) and the
UK Department for Business, Enterprise and Regulatory
Reform (BERR) [4-9]. The global warming potential in
carbon dioxide equivalents for methane and nitrous oxi-
des were calculated using conversion factors from the
IPCC third annual report [5]. Distances for business tra-
vel and transport of study equipment were estimated
using a web-based mileage calculator [10] for travel
between major cities and World Airport Codes distance
calculator [11] for smaller airports within a country. A
sample calculation of carbon emissions due to air travel
is provided (Table 3).
The carbon emissions due to energy consumption
(electricity, natural gas, heating oil and steam) and water
by the coordinating centre premises could not be calcu-
lated directly. This was because of the open plan form
of the trial offices and the fact that other non-trial activ-
ities were carried out in the same area during the con-
duct of both trials. Emissions were therefore estimated
on the basis of average per person emissions from office
space and the number of trial employees (9 in CRASH-
1 and 7 in CRASH-2). Electricity consumption of the
trial team was based upon percentage of total electricity
consumed by the trial office.
Carbon dioxide equivalents are reported separately for
CRASH-1 and CRASH-2 by source of emissions, includ-
ing emissions from coordination centre, trial related tra-
vel, commuting and drug box shipments. Emissions per
patient were calculated by dividing each trial’s total
greenhouse gas emissions estimated from the audit year
by the total number of patients randomized.
Table 1 NIHR Guidelines for Carbon Reduction in Clinical Trials1
Setting the research question and full use
of existing evidence
• Always carry out systematic reviews of existing evidence before new grant submission.
• Involve clinicians and patients in shaping applied research agendas.
Efficient study design • Efficient use of resources such as patient populations and patient time.
• Consider the possibility of answering several questions through one study.
• Involve methodologists in research design.
Study set up • Maximize professional assistance through research funders, clinical trial units, and NIHR networks to
minimize time spent on bureaucratic process.
• Decrease time spent on patient recruitment.
Avoid unnecessary data collection • Clear study protocols.
• Measure outcomes remotely when possible (phone, internet).
• If patient contact is necessary, utilize outcome assessors that are in close proximity to patients.
• Do not measure all outcomes on all patients if unnecessary.
Sensible clinical trial monitoring • Focus on issues that are critical for safety and wellbeing of study participants and reliability of results.
• Avoid monitoring that requires extensive travel to study sites; limit travel to sites only when there is
an issue or concern.
• Use centralized, systematic programs to ensure data authenticity and quality.
Good practice in research reporting • Report results of new primary research within updated systematic reviews of other relevant research.
• Ensure research reports are presented in a manner that allows information to be utilized by readers.
1 The NIHR Carbon Guidelines, (I. Roberts, personal communication, 20 October 2010)
Table 2 Trial activities included in the carbon audit
Coordination Centre • Electricity
• Natural Gas
• Steam
• Heating Oil
• Water
• Waste
Trial Related Travel • Train
• Flights
• Accommodation
Trial Team Commuting • Train
• Bus
• Underground
Freight Delivery • Air freight
• Diesel Van
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Results
The total emissions in carbon dioxide equivalents during
the one-year audit period were 181.3 tonnes for
CRASH-1 and 108.2 tonnes for CRASH-2 (Table 4).
Patient recruitment took 5.1 years for the CRASH-1
trial and 4.7 years for the CRASH-2 trial. Assuming the
audit year is representative of total trial emissions,
CRASH-1 was responsible for 924.6 tonnes of carbon
dioxide equivalents and CRASH-2 for 508.5 tonnes. In
CRASH-1 this would be equivalent to 681 round trip
flights from London to New York for one passenger,
and in CRASH-2 this would be equivalent to 374 round
trip flights. Overall, CRASH-2 emitted 45% less carbon
than CRASH-1.
The CRASH-1 trial recruited 10,008 patients, corre-
sponding to 92 kg of carbon dioxide per randomized
patient. The CRASH-2 trial recruited 20,211 patients,
corresponding to 25 kg of carbon dioxide per rando-
mized patient. CRASH-2 emitted 73% less carbon per
randomized patient than CRASH-1 (Figure 1).
Freight delivery of trial drugs
Freight delivery was the largest source of emissions for
the CRASH-1 trial (86.0 tonnes, 48% of total emissions).
It was the second largest source of emissions for the
CRASH-2 trial (34.2 tonnes, 32% of total emissions).
Air-transportation of treatment packs comprised the
majority of freight emissions in both trials contributing
81.0 tonnes in CRASH-1 (94% of freight delivery emis-
sions) and 29.0 tonnes in CRASH-2 (85% of freight
delivery emissions). Emissions due to freight delivery
emissions were 60% less in CRASH-2 as compared to
CRASH-1.
Coordination centre
The coordination centre was the second largest source
of emissions for the CRASH-1 trial (54.6 tonnes, 30% of
total emissions). It was the largest source of emissions
for the CRASH-2 trial (39.5 tonnes, 37% of total emis-
sions). Electricity use comprised the greatest proportion
of emissions of the coordination centre and contributed
29.0 tonnes during CRASH-1 (53% of coordination cen-
tre emissions) and 23.0 tonnes during CRASH-2 (58% of
coordination centre emissions). In both trials, the sec-
ond largest proportion of emissions in this category was
due to natural gas consumption. Overall, there was 28%
less carbon emitted due to the coordination centre from
CRASH-1 to CRASH-2.
Trial related travel
Trial related travel accounted for 37.3 tonnes (21% of
total emissions) in CRASH-1 and 31.1 tonnes (29% of
total emissions) in CRASH-2. Twenty-eight tonnes (75%
of travel emissions) were due to air-travel in CRASH-1,
and 29.0 tonnes (93% of travel emissions) were due to
air-travel in CRASH-2. The remainder of carbon emis-
sions in both trials was due to hotel stays. There was
Table 3 Sample calculation of trial related travel due to short-haul flights in the CRASH-1 trial
Total short-haul distance
travelled (km/yr)
Uplift factor
(%)
Emissions for short-haul flights CO2 emitted
(t/yr)
30,249 X 109 X 0.098 kgC02/pass.km=
0.001gCH4/pass.km=
0.004 gN20/pass.km=
3.2 +
3.3 × 10-5 +
1.3 × 105
Total = 3.3
Table 4 Summary of Greenhouse Gas emissions by trial
activity for the CRASH-1 and CRASH-2 trials
Source of
Emissions
CRASH-1
(tonnes of C02
equivalents/yr)
CRASH-2
(tonnes of C02
equivalents/yr)
Percentage
difference
in emissions
(%)
Electricity 29.0 23.0 -21
Natural Gas 13.0 9.7 -25
Heating Oil 7.6 5.9 -23
Steam 0.2 0.1 -50
Water 0.3 0.2 -33
Waste 4.5 0.6 -87
Coordination
centre total
54.6 39.5 -28
Train travel 0.7 0.2 -71
Air travel 28.0 29.0 +3
Accommodation 8.6 1.9 -78
Trial related
travel total
37.3 31.1 -17
Commuting-
Train
0.7 1.0 +43
Commuting- Bus 1.3 0.4 -69
Commuting-
Underground
1.4 2.0 +43
Trial team
commuting
total
3.4 3.4 0.0
Freight
deliveries- Diesel
vans
5.0 5.2 +4.0
Freight
deliveries- Air
freight
81.0 29.0 -64
Freight delivery
total
86.0 34.2 -60
Total Trial
Emissions
181.3 108.2 40
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17% less carbon emitted from CRASH-1 to CRASH-2
due to trial related travel.
Trial team commuting
Commuting accounted for 3.3 tonnes of emissions in
both CRASH-1 and CRASH-2. The majority of emis-
sions in both trials were due to underground tube travel,
contributing 1.4 tonnes (42% of commuting emissions)
in CRASH-1 and 2.0 tonnes (61% of commuting emis-
sions) in CRASH-2.
Discussion
The results of this comparative carbon audit show that the
CRASH-2 trial was considerably more carbon efficient
than CRASH-1, both in regards to the amount of carbon
emitted per randomized patient and in terms of total
emissions. The main reason was that the CRASH-2 trial
recruited more than twice as many patients in a shorter
time frame than CRASH-1. This in turn was facilitated by
the strong clinician interest in the research question, the
use of an established network of international collabora-
tors and the use of a simple trial design with data collec-
tion limited to key clinically relevant end points. The more
efficient recruitment in the CRASH-2 trial helped to mini-
mize carbon emissions per randomized patient.
Differences in the emissions arising from the delivery
of trial drugs accounted for a large part of the difference
in total carbon emissions between the trials. The trial
treatment in CRASH-2 was lighter and more compact
than in CRASH-1, weighing approximately 2.5 kg and 9
kg respectively. Each treatment pack in the CRASH-1
trial contained 11 glass vials approximately 5 cm in
height and width that had to be protected from break-
age during transit by means of protective packaging. On
the other hand, the CRASH-2 treatment pack contained
four small ampoules that required less protection.
Despite a larger number of delivery sites in CRASH-2,
emissions were nevertheless reduced in this sector illus-
trating how logistics can have an important impact on
carbon emissions.
Emissions from the coordination centre were slightly
lower for CRASH-2 than for CRASH-1. The carbon
emissions from the coordinating centre were based on
the number of office staff and there were fewer staff in
CRASH-2 than in CRASH-1. In the CRASH-1 trial,
handwritten data received by fax were double entered
by two staff members at the coordination centre.
CRASH-2 used direct data entry, which reduced the
need for data entry staff as well as reducing the risk of
transcription errors.
Trial-related travel often comprises an important
source of emissions in clinical trials and limiting unne-
cessary travel can reduce their carbon footprint [12].
Greater use of statistical data checking algorithms has
been suggested as a strategy to reduce the need for on-
site data monitoring and these methods were employed
in both trials [13]. Additionally, teleconferencing, video-
conferencing and web based training materials can be
used to reduce travel.
Strengths and limitations
This study collected information on all sources of car-
bon emissions for two large multi centre trials. The
same methodology was used to determine carbon emis-
sions for CRASH-1 and CRASH-2, helping to ensure a
valid comparison between trials. Furthermore, the audit
was carried out by an independent, third party organiza-
tion with extensive experience in quantifying and verify-
ing GHG emissions from operational activities.
However, our study has limitations. The audit period
was for only one year and extrapolation to the entire
trial may have led to inaccuracy. Data were collected
retrospectively, whereas prospective data collection
would have been more accurate. The energy consump-
tion of the coordination centre was not obtained by
direct measurement, which could lead to errors in esti-
mation of the true carbon emissions. Although the most
up-to-date standardized carbon conversion factors were
used, the science behind these equivalents is still devel-
oping and estimates may not represent actual carbon
dioxide equivalent emissions. However, since the same
conversion factors were applied to both trials, the com-
parison between trials and demonstrated reduction is
internally valid.
Conclusions
This study has shown that the efficiency of patient
recruitment is a major determinant of the environmen-
tal impact of a clinical trial. There is a limit to the
amount of greenhouse gases that can be emitted without
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Figure 1 Comparison of greenhouse gas emissions by activities
in the CRASH-1 and CRASH-2 trials.
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causing serious climate destabilization. If society decides
to allocate a proportion of its limited carbon budget to
obtaining information on the safety and effectiveness of
a health care intervention, then both researchers and
research regulators have the responsibilities to ensure
that the research is conducted as efficiently as is consis-
tent with patient safety and that it provides valid and
reliable information.
In the UK, there is a growing consensus that the regu-
lation and governance framework for clinical trials has
become an obstacle to their efficient conduct [14]. The
Academy of Medical Sciences has been commissioned by
the UK Government to undertake an independent review
of the regulation and governance of medical research
[15]. Although the CRASH-2 trial recruited patients
more rapidly than its predecessor, this was largely driven
by recruitment in Asia, South America and Africa, while
recruitment in the UK was much less than anticipated
largely due to these regulatory changes implemented after
CRASH-1 [16]. Streamlining and improving the regula-
tory environment has the potential to increase both the
carbon and cost effectiveness of medical research.
Although efforts to reduce the carbon footprint of clini-
cal trials are essential, it is important to acknowledge that
healthcare itself is a major source of carbon emissions
and that by ensuring the provision of safe and effective
healthcare, health research plays a central role in avoiding
medical waste. Pharmaceutical use is particularly carbon
intensive and makes a major contribution to the carbon
footprint of the NHS. The CRASH-1 trial showed that a
drug that had been used in the treatment of head injury
patients for over thirty years was at best ineffective, and
probably harmful [17]. The carbon cost of obtaining reli-
able information from well-conducted clinical studies is
likely to be dwarfed by that of using treatments that are
ineffective or harmful.
In summary, a number of strategies can be used to
reduce the carbon footprint of clinical research. Although
it is not always possible to reduce the weight and ship-
ping distance of trial materials, the use of lightweight
packaging can have an important impact on emissions.
Statistical data monitoring, web-based training materials
and tele-conferencing can help reduce travel. Direct data
entry can reduce the need for transcription and will also
lessen emissions from trial office space. While the focus
of this study was on emissions from non-commercial
clinical trials, the extent to which the principles might be
applied in pharmaceutical industry directed trials is open
to question. Industry led trials are often considerably
more complex and involve much more data collection
than non-commercial trials. On the other hand, it is
likely that the carbon footprint of industry led trials is
much larger, and the need to make emissions reductions
even more important.
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